Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.

Author: BenedettiFabio, BonizzoniErminio, BozzoliValentina, CapriaSaveria, ChiusoloPatrizia, CodegaPaolo, CupelliLuca, CupriAlessandra, De RisiClara, Di RenzoNicola, FedericoVincenzo, GuariniAttilio, MateraRosella, MazzaPatrizio, MengarelliAndrea, MessaAnna Rita, MussoMaurizio, PastoreDomenico, PerroneTommasina, ScimèRosanna, SeripaDavide, SpecchiaGiorgina

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

This study evaluates the effectiveness of antiemetic use during chemomobilization prior to autologous stem cell transplantation (ASCT) for patients receiving highly emetogenic preparative regimens. While studies have shown effective prevention of CINV during the conditioning phase with NK<sub>1</sub>RA-containing regimens, there have been no studies evaluating antiemetic use during chemomobilization prior to ASCT.
Paper Details　
Original Abstract of the Article :
Label="PURPOSE" NlmCategory="OBJECTIVE">Prevention of chemotherapy-induced nausea and vomiting (CINV) is particularly challenging for patients receiving highly emetogenic preparative regimens before autologous stem cell transplantation (ASCT) due to the daily and continuous emetogenic stimulus of th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727426/

データ提供：米国国立医学図書館（NLM）

Efficacy and Safety of Netupitant/Palonosetron for Chemotherapy-Induced Nausea and Vomiting

Chemotherapy-induced nausea and vomiting (CINV) is a common and distressing side effect of cancer treatment. This study investigates the efficacy and safety of a combination of netupitant and palonosetron in preventing CINV in patients with non-Hodgkin's lymphoma undergoing chemomobilization before autologous stem cell transplantation (ASCT). The authors examine the effectiveness of this antiemetic regimen in mitigating the severity and duration of CINV in this high-risk patient population.

Improving Symptom Management for Cancer Patients

The study highlights the potential of a combination of netupitant and palonosetron in effectively preventing CINV in patients undergoing highly emetogenic chemomobilization regimens. The findings suggest that this approach could significantly improve patient comfort and well-being during this challenging period of cancer treatment.

Optimizing Antiemetic Strategies for Cancer Therapy

The study emphasizes the importance of tailoring antiemetic strategies to the specific needs of cancer patients, considering the type and intensity of chemotherapy regimens. It underscores the need for effective antiemetic therapies to minimize the discomfort and distress associated with CINV, enhancing the overall quality of life for individuals undergoing cancer treatment.

Dr.Camel's Conclusion

The journey of cancer treatment can be arduous, with many challenges to overcome. This research, like a cool breeze in the desert, offers a potential way to alleviate one of the most distressing side effects of chemotherapy. By exploring innovative antiemetic combinations, we can improve the quality of life for cancer patients, providing them with greater comfort and strength as they navigate the path to healing.
Date :
  1. Date Completed 2022-01-06
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34533630

DOI: Digital Object Identifier

PMC8727426

Related Literature

Article Analysis
・Effects of netupitant and palonosetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.